This inventor holds 3 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Astellas Pharma Gmbh, Medivation Prostate Therapeutics, Inc.. Active years: 2023-2025.
Company Filing History:
3 out of 424 
3 out of 12 Years Active: 2023-2025
Title: Jason A Everett: Innovator in Pharmaceutical Formulations
Introduction
Jason A Everett is a notable inventor in the field of pharmaceutical formulations. He has made significant contributions to the development of treatments for hyperproliferative disorders. His work primarily focuses on the formulation of enzalutamide, a drug used in cancer therapy.
Latest Patents
Jason A Everett currently holds no patents. However, he has developed a formulation of a solid dispersion containing amorphous enzalutamide and hydroxypropyl methylcellulose acetate succinate. This formulation is designed for use in treating hyperproliferative disorders.
Career Highlights
Throughout his career, Jason has worked with prominent companies in the pharmaceutical industry. He has been associated with Astellas Pharma GmbH and Medivation Prostate Therapeutics, Inc. His experience in these organizations has contributed to his expertise in drug formulation and development.
Collaborations
Jason A Everett has collaborated with various professionals and organizations in the pharmaceutical sector. His work with Astellas Pharma and Medivation Prostate Therapeutics has allowed him to contribute to innovative solutions in cancer treatment.
Conclusion
Jason A Everett is a dedicated inventor whose work in pharmaceutical formulations has the potential to impact the treatment of hyperproliferative disorders. His contributions to the field, although not yet reflected in patents, demonstrate his commitment to advancing medical science.